Middle East & Africa Invasive Ductal Carcinoma Treatment Market Size & Outlook
Related Markets
MEA invasive ductal carcinoma treatment market highlights
- The MEA invasive ductal carcinoma treatment market generated a revenue of USD 325.7 million in 2024.
- The market is expected to grow at a CAGR of 7.3% from 2025 to 2030.
- In terms of segment, targeted therapy was the largest revenue generating therapy in 2024.
- Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
- Country-wise, Kuwait is expected to register the highest CAGR from 2025 to 2030.
MEA data book summary
| Market revenue in 2024 | USD 325.7 million |
| Market revenue in 2030 | USD 497.1 million |
| Growth rate | 7.3% (CAGR from 2025 to 2030) |
| Largest segment | Targeted therapy |
| Fastest growing segment | Immunotherapy |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Merck KGaA, Janssen Pharmaceuticals, Roche Holding AG ADR, AstraZeneca PLC, AbbVie Inc, Bristol-Myers Squibb Co, Macrogenics Inc, Celldex Therapeutics Inc |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.5% of the global invasive ductal carcinoma treatment market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,755.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Invasive Ductal Carcinoma Treatment Market Scope
Invasive Ductal Carcinoma Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Celldex Therapeutics Inc | View profile | 160 | 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, United States, 08827 | https://www.celldex.com |
| Janssen Pharmaceuticals | View profile | 1-10 | Titusville, New Jersey, United States, North America | https://www.xarelto-us.com |
| Macrogenics Inc | View profile | 339 | 9704 Medical Center Drive, Rockville, MD, United States, 20850 | https://www.macrogenics.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
| Roche Holding AG ADR | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Middle East & Africa invasive ductal carcinoma treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to invasive ductal carcinoma treatment market will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 70.92% in 2024. Horizon Databook has segmented the Middle East & Africa invasive ductal carcinoma treatment market based on targeted therapy, hormonal therapy, chemotherapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Middle East & Africa invasive ductal carcinoma treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa invasive ductal carcinoma treatment market databook
-
Our clientele includes a mix of invasive ductal carcinoma treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa invasive ductal carcinoma treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa invasive ductal carcinoma treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA invasive ductal carcinoma treatment market size, by country, 2018-2030 (US$M)
Middle East & Africa Invasive Ductal Carcinoma Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
